Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia : Determination of Biomarkers for the Prediction of Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
This is a prospective multicenter cohort of patients treated with the usual standard of care including systemic corticosteroid therapy with dexamethasone 6 mg / day.INCLUSION (D0): The patients are examined on the day of their hospital admission. After an initial eligibility check and if interest is expressed by the patient, a specific inclusion visit is carried out.FOLLOW-UP: Patients are clinically evaluated at least twice a day (Clinical examination, SpO2, vital signs) during hospitalization. Chest computed tomography and SARS-CoV-2 serology are performed on D0. Viral load is evaluated by the polymerase chain reaction which allowed the diagnosis of covid-19 in the 48 hours preceding D0 and on D7. The evaluation of conventional biomarkers of interest (blood count, hepatic assessment (ASAT, ALAT), serum creatinine, albuminemia, CRP, D-Dimers, LDH, Ferritin) are carried out on D0 (before the 1st dose of corticosteroids), D2 , J4 and J7. The evaluation of biomarkers of interest evaluated by mass spectrometry is carried out on D0 and D7 +/- 2 days.A follow-up call on D28 is carried out (telephone call, collection of vital status and hospitalizations)..
| Medienart: |
|
|---|
Klinische Studie| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
ClinicalTrials.gov - (2021) vom: 17. Dez. Zur Gesamtaufnahme - year:2021 |
|---|
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
610 |
|---|
| Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: November 6, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 27, 2021, Last updated: December 29, 2021 |
|---|
| Study ID: |
NCT04619693 |
|---|---|
| Veröffentlichungen zur Studie: |
|
| fisyears: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
CTG003569500 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | CTG003569500 | ||
| 003 | DE-627 | ||
| 005 | 20230425193341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210408s2021 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)CTG003569500 | ||
| 035 | |a (UBBS_Klinische_Studien)NCT04619693 | ||
| 035 | |a (UBBS_Klinische_Studien)RECHMPL20_0292 | ||
| 035 | |a (UBBS_Klinische_Studien)2020-A0206-33 | ||
| 035 | |a (UBBS_Klinische_Studien)PHRCI-20-013 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia |b Determination of Biomarkers for the Prediction of Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: November 6, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 27, 2021, Last updated: December 29, 2021 | ||
| 520 | |a This is a prospective multicenter cohort of patients treated with the usual standard of care including systemic corticosteroid therapy with dexamethasone 6 mg / day.INCLUSION (D0): The patients are examined on the day of their hospital admission. After an initial eligibility check and if interest is expressed by the patient, a specific inclusion visit is carried out.FOLLOW-UP: Patients are clinically evaluated at least twice a day (Clinical examination, SpO2, vital signs) during hospitalization. Chest computed tomography and SARS-CoV-2 serology are performed on D0. Viral load is evaluated by the polymerase chain reaction which allowed the diagnosis of covid-19 in the 48 hours preceding D0 and on D7. The evaluation of conventional biomarkers of interest (blood count, hepatic assessment (ASAT, ALAT), serum creatinine, albuminemia, CRP, D-Dimers, LDH, Ferritin) are carried out on D0 (before the 1st dose of corticosteroids), D2 , J4 and J7. The evaluation of biomarkers of interest evaluated by mass spectrometry is carried out on D0 and D7 +/- 2 days.A follow-up call on D28 is carried out (telephone call, collection of vital status and hospitalizations). | ||
| 650 | 2 | |a COVID-19 | |
| 650 | 2 | |a Pneumonia | |
| 650 | 2 | |a Pneumonia, Viral | |
| 650 | 4 | |a Medical Condition: Pneumonia, Viral, SARS-Cov-2 | |
| 650 | 4 | |a Study Type: Observational | |
| 650 | 4 | |a Recruitment Status: Terminated | |
| 650 | 4 | |a 610 | |
| 773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 17. Dez. |
| 773 | 1 | 8 | |g year:2021 |g day:17 |g month:12 |
| 856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04619693 |z kostenfrei |3 Volltext |
| 912 | |a GBV_CTG | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2021 |b 17 |c 12 | ||